{"doi":"10.1016/j.yebeh.2024.109922","title":"Brivaracetam effectiveness and tolerability in older and younger adults with epilepsy: EXPERIENCE, a pooled analysis of international data from retrospective studies","abstract":"This analysis assessed the effectiveness and tolerability of brivaracetam (BRV) in older (≥65 years of age) and younger (≥16 to <65 years of age) adults with epilepsy. This was a subgroup analysis from EXPERIENCE/EPD332, a pooled analysis of individual patient records from multiple independent, non-interventional studies of patients with epilepsy starting BRV in Australia, Europe, and the United States. Included patients had ≥6 months of follow-up data. Outcomes included responders (≥50 % reduction from baseline in seizure frequency), seizure freedom (no seizures within 3 months before the time point), and continuous seizure freedom (no seizures from baseline) at 12 months; BRV discontinuation during the whole study follow-up; and treatment-emergent adverse events (TEAEs) at 3, 6, and 12 months. Patients with missing data after BRV discontinuation were deemed non-responders/not seizure-free. Analysis populations included the Full Analysis Set (FAS; patients who received ≥1 BRV dose and had seizure type and age documented at baseline) and the modified FAS (FAS patients who had ≥1 seizure recorded during baseline). The FAS was used for all outcomes except seizure reduction. The FAS included 147 (8.9 %) patients aged ≥65 years and 1497 (91.1 %) aged ≥16 to <65 years. Compared with the younger subgroup, patients aged ≥65 years had a longer median epilepsy duration (33.0 years [n = 144] vs 17.0 years [n = 1460]) and lower median seizure frequency at index (2.0 seizures/28 days [n = 129] vs 4.0 seizures/28 days [n = 1256]), and less commonly had >1 prior antiseizure medication (106/141 [75.2 %] vs 1265/1479 [85.5 %]). At 12 months, a numerically higher percentage of patients aged ≥65 years versus the younger subgroup achieved ≥50 % seizure reduction (46.5 % [n = 71] vs 36.0 % [n = 751]), seizure freedom (26.0 % [n = 100] vs 13.9 % [n = 1011]), and continuous seizure freedom (22.0 % [n = 100] vs 10.7 % [n = 1011]). During the whole study follow-up, 43/147 (29.3 %) patients aged ≥65 years and 508/1492 (34.0 %) aged ≥16 to <65 years discontinued BRV. The incidence of TEAEs since the prior visit was similar in both subgroups at 3 months (≥65 years vs ≥16 to <65 years: 38/138 [27.5 %] vs 356/1404 [25.4 %]), 6 months (19/119 [16.0 %] vs 176/1257 [14.0 %]), and 12 months (8/104 [7.7 %] vs 107/1128 [9.5 %]). This real-world analysis suggests BRV was effective in patients aged ≥65 years and ≥16 to <65 years, with numerically higher effectiveness in the older subgroup. BRV was well tolerated in both subgroups.","journal":"Epilepsy & Behavior","year":2024,"id":436954,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":11,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9224,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1245767,"name":"Hervé Besson","orcid":null,"position":1,"is_corresponding":false},{"id":654741,"name":"Wendyl D’Souza","orcid":"0000-0002-1750-5131","position":2,"is_corresponding":false},{"id":1245768,"name":"Pavel Klein","orcid":null,"position":3,"is_corresponding":false},{"id":126447,"name":"Markus Reuber","orcid":null,"position":4,"is_corresponding":false},{"id":241370,"name":"Felix Rosenow","orcid":"0000-0002-3989-7471","position":5,"is_corresponding":false},{"id":1245769,"name":"Javier Salas‐Puig","orcid":null,"position":6,"is_corresponding":false},{"id":1245310,"name":"Víctor Soto Insuga","orcid":"0000-0002-8358-2901","position":7,"is_corresponding":false},{"id":814213,"name":"Bernhard J. Steinhoff","orcid":"0000-0001-5995-5862","position":8,"is_corresponding":false},{"id":618348,"name":"Adam Strzelczyk","orcid":"0000-0001-6288-9915","position":9,"is_corresponding":false},{"id":311438,"name":"Jerzy P. Szaflarski","orcid":"0000-0002-5936-6627","position":10,"is_corresponding":false},{"id":1245311,"name":"Dimitrios Bourikas","orcid":"0009-0005-4503-0734","position":11,"is_corresponding":false},{"id":1245770,"name":"Tony Daniels","orcid":null,"position":12,"is_corresponding":false},{"id":1245312,"name":"Florin Floricel","orcid":"0009-0008-4982-1092","position":13,"is_corresponding":false},{"id":1245771,"name":"David Friesen","orcid":null,"position":14,"is_corresponding":false},{"id":1245772,"name":"Cédric Laloyaux","orcid":null,"position":15,"is_corresponding":false},{"id":1245773,"name":"Vicente Villanueva","orcid":"0000-0003-2080-8042","position":16,"is_corresponding":false},{"id":1245309,"name":"Edward Faught","orcid":"0000-0001-7415-8044","position":0,"is_corresponding":true}],"reference_count":21,"raw_metadata":null,"created_at":"2026-07-19T02:00:16.989773Z","pmid":"38970892","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}